首页> 外文期刊>Allergy, Asthma & Immunology Research >Update in the Mechanisms of Allergen-Specific Immunotheraphy
【24h】

Update in the Mechanisms of Allergen-Specific Immunotheraphy

机译:过敏原特异性免疫疗法的机制更新

获取原文
           

摘要

Allergic diseases represent a complex innate and adoptive immune response to natural environmental allergens with Th2-type T cells and allergen-specific IgE predominance. Allergen-specific immunotherapy is the most effective therapeutic approach for disregulated immune response towards allergens by enhancing immune tolerance mechanisms. The main aim of immunotherapy is the generation of allergen nonresponsive or tolerant T cells in sensitized patients and downregulation of predominant T cell- and IgE-mediated immune responses. During allergen-specific immunotherapy, T regulatory cells are generated, which secrete IL-10 and induce allergen-specific B cells for the production of IgG4 antibodies. These mechanisms induce tolerance to antigens that reduces allergic symptoms. Although current knowledge highlights the role of T regulatory cell-mediated immunetolerance, definite mechanisms that lead to a successful clinical outcomes of allergen-specific immunotherapy still remains an open area of research.
机译:过敏性疾病代表对具有Th2型T细胞和过敏原特异性IgE优势的自然环境过敏原的复杂的先天性和过继性免疫反应。过敏原特异性免疫疗法是通过增强免疫耐受机制使针对过敏原的免疫反应失调的最有效治疗方法。免疫疗法的主要目的是在致敏患者中产生变应原无反应性或耐受性T细胞,并下调主要的T细胞和IgE介导的免疫反应。在过敏原特异性免疫治疗过程中,会产生T调节细胞,该细胞会分泌IL-10并诱导过敏原特异性B细胞产生IgG4抗体。这些机制诱导了对抗原的耐受性,从而减轻了过敏症状。尽管当前的知识凸显了T调节细胞介导的免疫耐受的作用,但导致过敏原特异性免疫疗法成功取得临床成果的确切机制仍然是一个开放的研究领域。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号